Cargando…

Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy

Dendritic cells (DCs) are antigen-presenting cells (APCs) that are essential for the activation of immune responses. In various malignancies, these immunostimulatory properties are exploited by DC-therapy, aiming at the induction of effective anti-tumor immunity by vaccination with ex vivo antigen-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Gulijk, Mandy, Dammeijer, Floris, Aerts, Joachim G. J. V., Vroman, Heleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289976/ https://www.ncbi.nlm.nih.gov/pubmed/30568653 http://dx.doi.org/10.3389/fimmu.2018.02759

Ejemplares similares

Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
por: Huber, Anne, et al.
Publicado: (2018)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
por: Lau, Sai Ping, et al.
Publicado: (2020)

Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?
por: Vroman, Heleen, et al.
Publicado: (2017)

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
por: Belderbos, Robert A., et al.
Publicado: (2019)

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
por: Hargadon, Kristian M.
Publicado: (2017)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
por: Datta, Jashodeep, et al.
Publicado: (2015)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
por: de Goeje, Pauline L., et al.
Publicado: (2018)

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
por: Dammeijer, Floris, et al.
Publicado: (2021)

Editorial: The development and plasticity of myeloid immunity in the lung
por: Schetters, Sjoerd T. T., et al.
Publicado: (2023)

Dendritic Cell-Based Immunotherapy in Lung Cancer
por: Stevens, Dieter, et al.
Publicado: (2021)

Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?
por: da Silva, Laís Teodoro, et al.
Publicado: (2018)

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
por: Noordam, Lisanne, et al.
Publicado: (2018)

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
por: Minnema-Luiting, Jorien, et al.
Publicado: (2018)

Dendritic Cell-Based Immunotherapy for Myeloid Leukemias
por: Schürch, Christian M., et al.
Publicado: (2013)

Dendritic Cells and Their Role in Immunotherapy
por: Gardner, Alycia, et al.
Publicado: (2020)

Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
por: Mankor, Joanne M., et al.
Publicado: (2020)

Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors
por: Dolcetti, Riccardo, et al.
Publicado: (2020)

Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer
por: Ni, Ling
Publicado: (2022)

Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases
por: Gordon, John R., et al.
Publicado: (2014)

Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
por: Peng, Xin, et al.
Publicado: (2021)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies
por: Nan, Yanyang, et al.
Publicado: (2023)

Tolerogenic Dendritic Cells: The Pearl of Immunotherapy in Organ Transplantation
por: Zhuang, Quan, et al.
Publicado: (2020)

Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
por: An, Bingzheng, et al.
Publicado: (2022)

Editorial: Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy
por: Plantinga, Maud, et al.
Publicado: (2022)

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy
por: Yin, Li, et al.
Publicado: (2022)

Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
por: Butterfield, Lisa H.
Publicado: (2013)

Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy
por: Patente, Thiago A., et al.
Publicado: (2019)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots
por: Pizzurro, Gabriela Andrea, et al.
Publicado: (2015)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
por: Matsumoto, Misako, et al.
Publicado: (2017)

The Natural Killer–Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy
por: Peterson, Erin E., et al.
Publicado: (2021)

Modulation of dendritic cell metabolism by an MPLA-adjuvanted allergen product for specific immunotherapy
por: Zimmermann, Jennifer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fkv1k9jpgv8gdn45asrksq56rj